UK Respiratory Drug Market 2021-2027: Industry Analysis, Trends, Growth, Opportunities, and Forecast

UK Respiratory Drug Market 2021-2027: Industry Analysis, Trends, Growth, Opportunities, and Forecast

UK respiratory drug market was $11.1 billion in 2018 and is anticipated to grow at a substantial rate of 7.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in Europe. Respiratory drugs are used for treatment of patient from asthma attacks and other respiratory ailments. As the prevalence of asthma and other diseases increases across UK, the demand of respiratory drugs is also expected to increase for treatment purposes. As per International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises of England, Scotland, Wales and Northern Ireland. Total population of the country in 2017 was 65 million, out of which about 18% are of geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by government and people can be forecast in the near future.

To

learn

more

about

this

report

request

a

free

sample

copy

@ https://www.omrglobal.com/request-sample/uk-respiratory-drug-market The UK respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been

classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the nation. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/ukrespiratory-drug-market Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drug to cater to a wide range of customers within and outside the region. The major players of the UK respiratory drug market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Market Segmentation UK Respiratory Drug Market by Route of Administration   

Oral Injectable Inhalable

UK Respiratory Drug Market by Application  

Asthma Chronic Obstructive Pulmonary Disease (COPD)

UK Respiratory Drug Market by End-User  

Homecare Hospitals and Clinics

Company Profiles

                

Air Liquide S.A. Aradigm Corp.

AstraZeneca PLC Baxter International Inc. Boehringer Ingelheim International GmbH F. Hoffmann-La Roche Ltd. GlaxoSmithKline PLC Merck & Co. Novartis AG Omron Healthcare Inc. Pfizer Inc. Pulmatrix Inc. ResMed Corp.

Savara, Inc. Sunovion Pharmaceuticals Takeda Pharmaceutical Company Ltd. Teva Pharmaceuticals Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-respiratory-drug-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404